Jason Kelly

Jason Kelly, CEO and co-founder of Ginkgo Bioworks, shares insights on delivering effective investor updates, highlighting transparency as key to building strong investor relationships. He delves into the revolutionary potential of synthetic biology, discussing how Ginkgo is helping customers optimize product creation. The conversation also tackles the ethical implications of DNA editing, and the importance of navigating biosecurity in biotech, balancing innovation with responsibility.

CEO and Co-Founder Gingko Bioworks, Jason Kelly discusses the wonder and challenges of bioengineering, the history of biotech, first principles thinking, super-voting shares, and applying AI to DNA engineering.

Jason Kelly, the Co-founder and CEO of Ginkgo Bioworks, and Michelle Rozo, VP of Technical Capabilities at In-Q-Tel, dive deep into the world of biotechnology. They discuss how the U.S. government transformed biotech into a $1 trillion industry and explore the transformative potential of AI in drug discovery. The duo also examines China’s growing ambitions in this field, raising questions about U.S. competitiveness. Additionally, they highlight ethical challenges and the need for strategic policies to foster innovation and enhance national security.

Join Jason Kelly, co-founder of Ginkgo Bioworks, and Dawn Meyerriecks, former CIA Deputy Director for Science and Technology, as they delve into the pivotal role of life sciences in national security. They explore the dual-use potential of biotechnology and the urgent need for ethical oversight amid rising geopolitical tensions. Key topics include pandemic preparedness, the importance of vaccine production, and wastewater monitoring for viral trends. Their conversation emphasizes the necessity for innovation and investment to safeguard national resilience against emerging biological threats.

Jason Kelly, co-founder and CEO of Ginkgo Bioworks and an MIT Ph.D. in Biological Engineering, dives into the intersection of AI and synthetic biology. He discusses how DNA acts as a code akin to software, highlighting innovations in protein engineering. Kelly illustrates pandemic preparedness through advancements in synthetic biology and the importance of AI in drug discovery. The conversation sheds light on corporate governance in biotech startups and the evolutionary insights that can optimize biological systems for future research.

Today John Cumbers talks with Jason Kelly, Co-founder and CEO of Ginkgo Bioworks. Together they will discuss synthetic biology’s coming of age” and get Jason’s take on several topics, such as the history of programmable biology, Sam Altman, Ai and the role of AI in biology, and the new congressional commission covering national security and emerging biotechnology. Check out this week's sponsor: Twist Bioscience Jason Kelly is a co-founder and the CEO of Ginkgo Bioworks. He obtained his doctorate in Bioengineering from MIT in 2008, where he worked on engineering bacteria to produce biofuels. In 2009, Kelly co-founded Ginkgo Bioworks along with four other co-founders. Under his leadership, Ginkgo has grown to become one of the leading companies in the field of synthetic biology, with a focus on developing custom microbes for a wide range of applications, including pharmaceuticals, agriculture, and industrial chemicals. Jason has been recognized for his contributions to synthetic biology, receiving several awards, including MIT Technology Review's Innovator Under 35 and Forbes' 30 Under 30 in Energy. Connect with Matt: @jrkelly Connect with John: @johncumbers Stay updated on the latest news in synthetic biology, check out our weekly newsletter, and follow us on social media: Twitter | LinkedIn | Facebook Be sure you make it to our SynBioBeta events! Click here for more information.

Jason Kelly, CEO of Ginkgo Bioworks and pioneer in industrializing biology, discusses the future of biotech with cutting-edge insights. He argues that AI and lab automation will redefine science, making biology akin to software. Kelly highlights challenges in programming biology and the need for splitting lab work from design. He explores the impact of regulations, the burgeoning field of human enhancement, and how China's advancements could reshape the industry. Join him in envisioning a future where machines and AI drive scientific discovery.

Join Bloomberg Originals correspondent Vanessa Perdomo, along with sports leaders Paul Caine, Wayne Kimmel, and F1 driver Pierre Gasly. They dive into the booming world of sports investing, revealing how technology is reshaping the landscape. Paul discusses creating premium event experiences, while Wayne highlights the enormous potential of sports travel packages. Jason chats with Pierre about athletes transitioning into ownership roles, emphasizing the economic rise of Formula 1 in the U.S. Exciting insights into how personal connections shape the competitive world of sports!

Join Jason Kelly, CEO of Ginkgo Bioworks, and Matthew Harrison, a biotech analyst at Morgan Stanley, as they delve into Moderna's innovative journey in biotech. They discuss how Moderna's mRNA technology acts like the software of life, revolutionizing vaccine development. The conversation touches on the evolution of biotechnology, strategic shifts from traditional methods to advanced automation, and the financial dynamics shaping the pharmaceutical landscape. Discover how Moderna's unique business model positions it for future breakthroughs in drug development.

Jason Kelly, co-founder and CEO of Ginkgo Bioworks, shares insights on how automation and AI are revolutionizing biotech. He discusses the importance of generating standardized experimental datasets for effective machine learning, allowing faster R&D processes. Jason highlights the company's shift to an automation-first model and modular lab technologies that democratize advanced experimentation. The conversation also touches on reducing drug development costs and the strategic importance of biotech in national security.